Literature DB >> 8911899

Congenital muscular dystrophy with laminin alpha 2 chain deficiency: identification of a new intermediate phenotype and correlation of clinical findings to muscle immunohistochemistry.

R Herrmann1, V Straub, K Meyer, T Kahn, M Wagner, T Voit.   

Abstract

UNLABELLED: The laminins comprise of a family of heterotrimeric proteins of the extracellular matrix. The crossshaped proteins consist of a heavy alpha-chain and two light chains, called beta and gamma. Each group of chains, classified on their sequence identity and domain organization, include different isoforms. A deficiency of the alpha 2 chain of laminin-2, previously termed merosin or M component, was shown to be responsible for one form of congenital muscular dystrophy (CMD). We investigated muscle biopsies of 20 patients with the clinical diagnosis of CMD and histological evidence of muscular dystrophy for the expression of different laminin chains. Patients with evidence of pachygyria/lissencephaly of the CNS were excluded from this series. The immunohistochemical analysis was correlated to clinical findings and MRI data of the brain. Of 20 patients, 11 (55%) revealed complete or near-complete deficiency of the alpha 2 chain in their skeletal muscle specimens. So far none of these patients became ambulant. Of 20 patients 2 showed partial but clear-cut alpha 2 chain-deficiency. These two patients became ambulant at 18 months and 3 years. All 13 patients with complete or partial alpha 2 chain-deficiency demonstrated cerebral white matter changes on MRI. In contrast, 6/7 CMD patients with normal alpha 2 chain expression became ambulant and none of the 6/7 tested showed evidence of cerebral abnormal T2 sequence signal of the myelin on MRI.
CONCLUSION: Our findings emphasize the use of immunohistochemistry for laminin alpha 2 as a diagnostic tool in defining CMD and characterize a milder phenotype with partial alpha 2 chain-deficiency.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8911899     DOI: 10.1007/bf02282889

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  29 in total

1.  Proceedings of the 27th ENMC sponsored workshop on congenital muscular dystrophy. 22-24 April 1994, The Netherlands.

Authors:  V Dubowitz; M Fardeau
Journal:  Neuromuscul Disord       Date:  1995-05       Impact factor: 4.296

2.  Merosin, a tissue-specific basement membrane protein, is a laminin-like protein.

Authors:  K Ehrig; I Leivo; W S Argraves; E Ruoslahti; E Engvall
Journal:  Proc Natl Acad Sci U S A       Date:  1990-05       Impact factor: 11.205

Review 3.  Laminin and other basement membrane components.

Authors:  G R Martin; R Timpl
Journal:  Annu Rev Cell Biol       Date:  1987

4.  Abnormal localization of laminin subunits in muscular dystrophies.

Authors:  Y K Hayashi; E Engvall; E Arikawa-Hirasawa; K Goto; R Koga; I Nonaka; H Sugita; K Arahata
Journal:  J Neurol Sci       Date:  1993-10       Impact factor: 3.181

5.  22nd ENMC sponsored workshop on congenital muscular dystrophy held in Baarn, The Netherlands, 14-16 May 1993.

Authors:  V Dubowitz
Journal:  Neuromuscul Disord       Date:  1994-01       Impact factor: 4.296

6.  Murine muscular dystrophy caused by a mutation in the laminin alpha 2 (Lama2) gene.

Authors:  H Xu; X R Wu; U M Wewer; E Engvall
Journal:  Nat Genet       Date:  1994-11       Impact factor: 38.330

7.  Clinical phenotype in congenital muscular dystrophy: correlation with expression of merosin in skeletal muscle.

Authors:  J Philpot; C Sewry; J Pennock; V Dubowitz
Journal:  Neuromuscul Disord       Date:  1995-07       Impact factor: 4.296

8.  Familial concordance of brain magnetic resonance imaging changes in congenital muscular dystrophy.

Authors:  J Philpot; H Topaloglu; J Pennock; V Dubowitz
Journal:  Neuromuscul Disord       Date:  1995-05       Impact factor: 4.296

9.  Two distinct cell-binding domains in laminin can independently promote nonneuronal cell adhesion and spreading.

Authors:  S L Goodman; R Deutzmann; K von der Mark
Journal:  J Cell Biol       Date:  1987-07       Impact factor: 10.539

10.  A role for the dystrophin-glycoprotein complex as a transmembrane linker between laminin and actin.

Authors:  J M Ervasti; K P Campbell
Journal:  J Cell Biol       Date:  1993-08       Impact factor: 10.539

View more
  12 in total

Review 1.  The congenital muscular dystrophies: recent advances and molecular insights.

Authors:  Jerry R Mendell; Daniel R Boué; Paul T Martin
Journal:  Pediatr Dev Pathol       Date:  2006 Nov-Dec

2.  Evidence-based guideline summary: evaluation, diagnosis, and management of congenital muscular dystrophy: Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Issues Review Panel of the American Association of Neuromuscular & Electrodiagnostic Medicine.

Authors:  Peter B Kang; Leslie Morrison; Susan T Iannaccone; Robert J Graham; Carsten G Bönnemann; Anne Rutkowski; Joseph Hornyak; Ching H Wang; Kathryn North; Maryam Oskoui; Thomas S D Getchius; Julie A Cox; Erin E Hagen; Gary Gronseth; Robert C Griggs
Journal:  Neurology       Date:  2015-03-31       Impact factor: 9.910

3.  Assignment of a form of congenital muscular dystrophy with secondary merosin deficiency to chromosome 1q42.

Authors:  M Brockington; C A Sewry; R Herrmann; I Naom; A Dearlove; M Rhodes; H Topaloglu; V Dubowitz; T Voit; F Muntoni
Journal:  Am J Hum Genet       Date:  2000-02       Impact factor: 11.025

Review 4.  The expanding phenotype of laminin alpha2 chain (merosin) abnormalities: case series and review.

Authors:  K J Jones; G Morgan; H Johnston; V Tobias; R A Ouvrier; I Wilkinson; K N North
Journal:  J Med Genet       Date:  2001-10       Impact factor: 6.318

5.  Merosin-deficient congenital muscular dystrophy. Partial genetic correction in two mouse models.

Authors:  W Kuang; H Xu; P H Vachon; L Liu; F Loechel; U M Wewer; E Engvall
Journal:  J Clin Invest       Date:  1998-08-15       Impact factor: 14.808

6.  Merosin-deficient congenital muscular dystrophy (CMD): a study of 25 Brazilian patients using MRI.

Authors:  Claudia C Leite; Leandro T Lucato; Maria G M Martin; Lucio G Ferreira; Maria B D Resende; Mary S Carvalho; Suely K N Marie; J Randy Jinkins; Umbertina C Reed
Journal:  Pediatr Radiol       Date:  2005-03-05

Review 7.  The role of laminins in the organization and function of neuromuscular junctions.

Authors:  Robert S Rogers; Hiroshi Nishimune
Journal:  Matrix Biol       Date:  2016-09-07       Impact factor: 11.583

8.  Abnormalities of dystrophin, the sarcoglycans, and laminin alpha2 in the muscular dystrophies.

Authors:  K J Jones; S S Kim; K N North
Journal:  J Med Genet       Date:  1998-05       Impact factor: 6.318

9.  Laminin α2 Deficiency-Related Muscular Dystrophy Mimicking Emery-Dreifuss and Collagen VI related Diseases.

Authors:  Isabelle Nelson; Tanya Stojkovic; Valérie Allamand; France Leturcq; Henri-Marc Bécane; Dominique Babuty; Annick Toutain; Christophe Béroud; Pascale Richard; Norma B Romero; Bruno Eymard; Rabah Ben Yaou; Gisèle Bonne
Journal:  J Neuromuscul Dis       Date:  2015-09-02

10.  Utility of Immunohistochemistry and Western Blot in Profiling Clinically Suspected Cases of Congenital Muscular Dystrophy.

Authors:  Radhika Mhatre; Deepha Sekar; Jessiena Ponmalar; Madhu Nagappa; Preethish-Kumar Veeramani; Kiran Polavarapu; Seena Vengalil; Nalini Atchayaram; Gayathri Narayanappa
Journal:  Ann Indian Acad Neurol       Date:  2020-07-24       Impact factor: 1.383

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.